# C_2017240EN.01001301.xml

| 25.7.2017 | EN | Official Journal of the European Union | C 240/13 |
| --- | --- | --- | --- |

25.7.2017

EN

Official Journal of the European Union

C 240/13

---

Prior notification of a concentration

(Case M.8556 — Carlyle/GTCR/Albany Molecular Research)

Candidate case for simplified procedure

(Text with EEA relevance)

(2017/C 240/07)

| 1. | On 17 July 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which The Carlyle Group (‘Carlyle’, United States) and GTCR LLC (‘GTCR’, United States) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Albany Molecular Research, Inc. (‘AMRI’, United States) by way of a purchase of shares. |
| --- | --- |

1.

On 17 July 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which The Carlyle Group (‘Carlyle’, United States) and GTCR LLC (‘GTCR’, United States) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Albany Molecular Research, Inc. (‘AMRI’, United States) by way of a purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   for Carlyle: global alternative asset manager, which manages funds that invest globally across four investment disciplines: corporate private equity; real assets; global market strategies; and solutions,
  —   for GTCR: private equity firm founded focused on investing in growth companies in the financial services and technology, healthcare, technology, media and telecommunications and growth business services industries,
  —   for AMRI: global contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Carlyle: global alternative asset manager, which manages funds that invest globally across four investment disciplines: corporate private equity; real assets; global market strategies; and solutions,

for Carlyle

—   for GTCR: private equity firm founded focused on investing in growth companies in the financial services and technology, healthcare, technology, media and telecommunications and growth business services industries,

for GTCR

—   for AMRI: global contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services.

for AMRI

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8556 — Carlyle/GTCR/Albany Molecular Research, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8556 — Carlyle/GTCR/Albany Molecular Research, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---